Membrane raft disruption results in neuritic retraction prior to neuronal death in cortical neurons

BioScience Trends

Volumn 6, Issue 4, 2012, Pages 183-191

  Whitehead, Shawn N ^a   Gangaraju, Sandhya ^a   Aylsworth, Amy ^a   Hou, Sheng T ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Axonal damage; Cortical neurons; Membrane raft; Neuritic retraction; Neuronal death; Time lapse imaging

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; BETA CYCLODEXTRIN DERIVATIVE; CYTOSKELETON PROTEIN; METHYL BETA CYCLODEXTRIN; METHYL-BETA-CYCLODEXTRIN; MORPHOLINE DERIVATIVE;

ANIMAL; ARTICLE; BRAIN CORTEX; CELL DEATH; CELL MEMBRANE; CELL SURVIVAL; DRUG EFFECT; METABOLISM; MICROTUBULE; MOUSE; NEURITE; PATHOLOGY; TIME LAPSE IMAGING;

ANIMALS; BETA-CYCLODEXTRINS; CELL DEATH; CELL SURVIVAL; CEREBRAL CORTEX; CYTOSKELETAL PROTEINS; MEMBRANE MICRODOMAINS; MICE; MICROTUBULES; MORPHOLINES; NEURITES; TIME-LAPSE IMAGING;

EID: 84866850013     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.4.183     Document Type: Article

References (44)

1. Pike LJ. Rafts defined: A report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res. 2006; 47:1597-1598.
2. Pike LJ. The challenge of lipid rafts. J Lipid Res. 2009; 50 (Suppl S):323-328.
3. Hering H, Lin CC, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci. 2003; 23:3262-3271.
4. Guirland C, Suzuki S, Kojima M, Lu B, Zheng JQ. Lipid rafts mediate chemotropic guidance of nerve growth cones. Neuron. 2004; 42:51-62.
5. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000; 1:31-39.
6. Korade Z, Kenworthy AK. Lipid rafts, cholesterol, and the brain. Neuropharmacology. 2008; 55:1265-1273.
7. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997; 387:569-572.
8. Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, Miyazaki M, Nakajima N, Okada M, Saito T. Cutting edge: Negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J Immunol. 2002; 168:541-544.
9. Foger N, Marhaba R, Zoller M. Involvement of CD44 in cytoskeleton rearrangement and raft reorganization in T cells. J Cell Sci. 2001; 114:1169-1178.
10. Dremina ES, Sharov VS, Schoneich C. Protein tyrosine nitration in rat brain is associated with raft proteins, flotillin-1 and alpha-tubulin: Effect of biological aging. J Neurochem. 2005; 93:1262-1271.
11. Kawabe Ji, Okumura S, Nathanson MA, Hasebe N, Ishikawa Y. Caveolin regulates microtubule polymerization in the vascular smooth muscle cells. Biochemical and Biophysical Research Communications. 2006; 342:164-169.
12. Levitan I, Gooch KJ. Lipid rafts in membrane-cytoskeleton interactions and control of cellular biomechanics: Actions of oxLDL. Antioxid Redox Signal. 2007; 9:1519-1534.
13. Abulrob A, Tauskela JS, Mealing G, Brunette E, Faid K, Stanimirovic D. Protection by cholesterol-extracting cyclodextrins: A role for N-methyl-D-aspartate receptor redistribution. J Neurochem. 2005; 92:1477-1486.
14. Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, Masliah E. Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alphasynucleinopathy. J Neurochem. 2006; 98:1032-1045.
15. Huang P, Xu W, Yoon SI, Chen C, Chong PL, Liu-Chen LY. Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells. Biochem Pharmacol. 2007; 73:534-549.
16. Gibson NJ, Tolbert LP, Oland LA. Roles of specific membrane lipid domains in EGF receptor activation and cell adhesion molecule stabilization in a developing olfactory system. PLoS One. 2009; 4:e7222.
17. Sjogren B, Csoregh L, Svenningsson P. Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures. Naunyn Schmiedebergs Arch Pharmacol. 2008; 378:441-446.
18. Sillence DJ, Puri V, Marks DL, Butters TD, Dwek RA, Pagano RE, Platt FM. Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res. 2002; 43:1837-1845.
19. Szoke E, Borzsei R, Toth DM, Lengl O, Helyes Z, Sandor Z, Szolcsanyi J. Effect of lipid raft disruption on TRPV1 receptor activation of trigeminal sensory neurons and transfected cell line. Eur J Pharmacol. 2010; 628:67-74.
20. Sjogren B, Svenningsson P. Depletion of the lipid raft constituents, sphingomyelin and ganglioside, decreases serotonin binding at human 5-HT7(a) receptors in HeLa cells. Acta Physiologica. 2007; 190:47-53.
21. Giovanni A, Keramaris E, Morris EJ, Hou ST, O'Hare M, Dyson N, Robertson GS, Slack RS, Park DS. E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. J Biol Chem. 2000; 275:11553-11560.
22. Hou ST, Jiang SX, Desbois A, Huang D, Kelly J, Tessier L, Karchewski L, Kappler J. Calpain-cleaved collapsin response mediator protein-3 induces neuronal death after glutamate toxicity and cerebral ischemia. J Neurosci. 2006; 26:2241-2249.
23. Michaelis ML, Ranciat N, Chen Y, Bechtel M, Ragan R, Hepperle M, Liu Y, Georg G. Protection against betaamyloid toxicity in primary neurons by paclitaxel (Taxol). J Neurochem. 1998; 70:1623-1627.
24. Fatokun AA, Stone TW, Smith RA. Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons. Exp Brain Res. 2008; 186:151-160.
25. Bruses JL, Chauvet N, Rutishauser U. Membrane lipid rafts are necessary for the maintenance of the (alpha)7 nicotinic acetylcholine receptor in somatic spines of ciliary neurons. J Neurosci. 2001; 21:504-512.
26. Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem. 2004; 89:24-32.
27. Leuba G, Walzer C, Vernay A, Carnal B, Kraftsik R, Piotton F, Marin P, Bouras C, Savioz A. Postsynaptic density protein PSD-95 expression in Alzheimer's disease and okadaic acid induced neuritic retraction. Neurobiol Dis. 2008; 30:408-419.
28. Levin EC, Acharya NK, Sedeyn JC, Venkataraman V, D'Andrea MR, Wang HY, Nagele RG. Neuronal expression of vimentin in the Alzheimer's disease brain may be part of a generalized dendritic damage-response mechanism. Brain Res. 2009; 1298:194-207.
29. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002; 298:789-791.
30. Plowey ED, Cherra SJ, III, Liu YJ, Chu CT. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem. 2008; 105:1048-1056.
31. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006; 52:587-593.
32. Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet. 2006; 7:306-318.
33. Hou ST, Keklikian A, Slinn J, O'Hare M, Jiang SX, Aylsworth A. Sustained up-regulation of semaphorin 3A, Neuropilin1, and doublecortin expression in ischemic mouse brain during long-term recovery. Biochem Biophys Res Commun. 2008; 367:109-115.
34. Flood DG, Coleman PD. Dendritic regression dissociated from neuronal death but associated with partial deafferentation in aging rat supraoptic nucleus. Neurobiol Aging. 1993; 14:575-587.
35. Terry RD, Katzman R. Life span and synapses: Will there be a primary senile dementia? Neurobiol Aging. 2001; 22:347-348.
36. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30:572-580
37. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: Mechanisms of neuroprotection. Prog Neurobiol. 2009; 88:64-75.
38. Ponce J, de la Ossa NP, Hurtado O, Millan M, Arenillas JF, Davalos A, Gasull T. Simvastatin reduces the association of NMDA receptors to lipid rafts: A cholesterol-mediated effect in neuroprotection. Stroke. 2008; 39:1269-1275.
39. Hurtado O, Moro MA, Cardenas A, Sanchez V, Fernandez- Tome P, Leza JC, Lorenzo P, Secades JJ, Lozano R, Davalos A, Castillo J, Lizasoain I. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: Effects on glutamate transport. Neurobiol Dis. 2005; 18:336-345.
40. Hurtado O, Pradillo JM, Fernandez-Lopez D, Morales JR, Sobrino T, Castillo J, Alborch E, Moro MA, Lizasoain I. Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords neuroprotection in experimental stroke. Neurobiol Dis. 2008; 29:123-131.
41. Tian G, Kong Q, Lai L, Ray-Chaudhury A, Liang Glenn LC. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: A potential role in Alzheimer's disease. J Neurochem. 2010; 113:978-989.
42. Munro S. Lipid rafts: Elusive or illusive? Cell. 2003; 115:377-388.
43. Hancock JF. Lipid rafts: Contentious only from simplistic standpoints. Nat Rev Mol Cell Biol. 2006; 7:456-462.
44. Babiychuk EB, Draeger A. Biochemical characterization of detergent-resistant membranes: A systematic approach. Biochem J. 2006; 397:407-416.